Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Stroke, and Mortality in Patients with Type 2 Diabetes

被引：0
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, 1 1 5 Sendagi Bunkyo Ku, Tokyo 1138602, Japan
来源：
CARDIOVASCULAR DRUGS AND THERAPY | 2023年 / 37卷 / 04期
关键词：
OUTCOMES;
D O I：
10.1007/s10557-022-07374-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：619 / 620
页数：2
相关论文
共 50 条
  • [31] Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-glucose Cotransporter-2 Inhibitors - A Case Series
    Sharma, Purva V.
    Jobanputra, Yash B.
    Lewin, Karen
    Bagatell, Stuart
    Lichtstein, Daniel M.
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (02) : 156 - 160
  • [32] Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
    Shapiro, Samantha B.
    Yin, Hui
    Yu, Oriana Hoi Yun
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 349 - 349
  • [33] Impact of introducing sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes without complications
    Mehta, R.
    Bahia, L.
    Saif, A.
    Musso, C.
    Deyneli, O.
    Subramaniam, S.
    Gabriel, Z.
    Goncalves, S.
    Solorzano, J.
    Vasnawala, H.
    Schabert, V.
    Mihajlovic, J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [34] Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review
    Radholm, Karin
    Wu, Jason H. Y.
    Wong, Muh Geot
    Foote, Celine
    Fulcher, Gregory
    Mahaffey, Kenneth W.
    Perkovic, Vlado
    Neal, Bruce
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 140 : 118 - 128
  • [35] Risk of hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A nationwide cohort study
    Bea, Sungho
    Jeong, Han Eol
    Park, Sohee
    Chang, Yoosoo
    Sinn, Dong Hyun
    Yu, Oriana Hoi Yun
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 7 - 8
  • [36] Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
    Georgiou, Petros
    Shi, Wangpan
    Serhiyenia, Tatsiana
    Akram, Aqsa
    Proute, Matthew C.
    Pradeep, Roshini
    Kerolos, Mina E.
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [37] Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes
    Lam, Steven Ho Man
    Alam, Uazman
    Lip, Gregory Yoke Hong
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 223 : 183 - 185
  • [38] Sodium-Glucose Cotransporter-2 Inhibitors in Depression
    Liebers, David T.
    Ebina, Wataru
    Iosifescu, Dan V.
    HARVARD REVIEW OF PSYCHIATRY, 2023, 31 (04) : 214 - 221
  • [39] Gout and sodium-glucose cotransporter-2 inhibitors
    Lai, Shih-Wei
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (01) : 112 - 113
  • [40] Sodium-glucose cotransporter-2 inhibitors in cardiovascular disease: a gaseous solution
    Durante, William
    MEDICAL GAS RESEARCH, 2025, 15 (02): : 206 - 207
12345